LIVE: HHS Holds Mold Surveillance Roundtable

Live News Network
1.4K followers
62 Video Views·Sep 18, 2026
The U.S. Department of Health and Human Services holds a Mold Surveillance Roundtable at 11 a.m. ET on Sept. 18.
AI Generated·May contain errors
Video Summary
AI GeneratedHHS Secretary Robert F. Kennedy Jr., CDC officials, and medical experts convened to address systemic failures in diagnosing and treating fungal and mold diseases. The discussion highlighted high mortality rates, the \"diagnostic odyssey\" patients face due to physician unawareness, and the urgent need for rapid diagnostics, increased R&D, and better medical education to reduce preventable deaths.
I'm going to work the mics first.
Red is on.
Oh, jeez, and it's loud.
Sorry, we blew out everyone's eardrums.
All right, so good morning and welcome to HHS.
I have the pleasure of moderating this round table today
and we're going to try to keep it on schedule.
That's my hardest job.
So what we're going to do is we're going to do
a brief round of introductions.
We're going to have remarks
and then we will have questions for our panelists.
I found that it's more fun
when you talk to each other as well.
So if you do have questions for each other
and we want to engage in some dialogue,
please feel free to have at it.
I will blow the whistle if we start running long though.
So I'm Dr. Sarah Brenner.
I'm a senior counselor for public health
here in the immediate office of the secretary.
And I am going to turn it over to my colleague,
Dr. Schwartz, to introduce herself
and we'll carry on from there.
Go ahead.
Hi, I'm Dr. Erica Schwartz.
I am the five week old CDC director.
Oh, I'm Congressman Vince Fong
representing the 20th district in California.
My name is Rob Purdy.
I'm a fungal meningitis patient
and the president and co-founder of MyCare Foundation,
the first hand fungal patient advocacy organization.
Good morning.
I'm Dr. Lucy Witt from Emory University
and I'm one of the co-PIs
of the Georgia Emerging Infections Program.
And I oversee our invasive mycotics disease surveillance.
Go over here.
Yeah, good morning.
I'm Tom Chiller.
I spent the last 25 years at CDC
running the Mycotic Diseases Branch.
And now I work at a small fungal diagnostic company
called IMMI based in Norman, Oklahoma,
where I am the chief medical officer.
Hi, I'm Peter Pappas,
professor of medicine at University of Alabama
in Birmingham and Division of Infectious Diseases
and also the PI of the central unit of the Mycosis Center.
Hello, good morning.
My name is Dr. Nancy Chow
and I'm chief of CDC's Mycotic Diseases Branch,
which serves as the national fungal leader
in fungal disease public health.
Wonderful, thank you all again for being here.
All right, it's now my great pleasure to introduce
and welcome our HHS secretary,
Robert F. Kennedy Jr. for opening remarks.
Go ahead, sir.
Thank you, Sarah.
Thank you all for being here today.
And this is the 10th anniversary
of Fungal Disease Awareness Week
and we wanted to do this this week,
but this is something that I've been wanting to do
since the day that I got in here
and I'll explain why in a second.
It's an honor to join you in the fight
not only to control fungal disease in the United States,
but to figure out ways of how to prevent them.
And I want to thank Congressman Vince Fong for being here
and for his efforts to draw attention
to this issue in the house.
He introduced a resolution yesterday
that would boost awareness and improve the diagnosis,
treatment, and prevention of fungal disease
in the United States.
Congressman, I know that this is personal to you
because you represent California,
the Central Valley, the Sonoma Valley disease.
Thank you for your work bringing attention to this.
And I went on undiagnosed for a long time.
I have a son who had a chronic mold infestation
and ended up in his sinuses.
And he saw 89 doctors before he was properly diagnosed.
And ultimately he had to move to Phoenix, Arizona.
And the reason that he moved to Phoenix
because he had a cousin who had the same thing,
moved to Phoenix and the mold disease went away
when he got to Phoenix.
It's completely dictated to his life.
I saw the struggles that he went through
and seeing doctor after doctor
who just did not recognize what they were seeing
and could not, they were trying as hard as they could,
but there just was not enough information out there
and we're not getting information.
I know because of my son's struggles,
I now know so many people who are affected by this.
And to me, it's a lot like Lyme disease
and some of these others.
Long COVID, people, the patients who have this
endure kind of a nightmare of being dismissed.
And doctors get frustrated dealing with them
because nothing works.
Antibiotics don't work.
And so a lot of the antifungal treatments don't work
and they don't get better.
And that's frustrating for the doctor and for the patient.
But I think that there's so many more people
who are affected by this disease
that we don't know about in this country.
And we need to figure out the causes
about why this is exploding.
And is it building materials in our houses
or what is causing this and how do we prevent it?
Are there ways, you know, my son moved into a house
in Phoenix that was built for mold resistance.
The walls are, you know, they use a special carbon paint.
They have an air conditioning system
that keeps out mold and the whole house is designed for it.
And the way, the reason he moved there
is because he ran into some friends
who had the exact same problem as he.
And they were, you know, they were people
who had done very well and they built their lives
around just controlling for mold.
And they go, there are certain bars
that they can't go to in Phoenix.
There's certain hotels, there's certain shops
they can't go to because it will reenact the mold.
My son can now leave Phoenix.
When he does, he has, there are certain cities
that are very difficult from San Francisco.
A lot of the East Coast cities that have a high humidity
and high mold and then he has to pick the hotels
that he goes to to find newer buildings.
And he only discovered this
because he went on this long journey that was,
you know, incredible.
It was like, if you ever see the Odyssey,
it was worse than, you know, what Ulysses went through,
the stuff that he had to go through.
He had the resources to do that
and to find a lot of functional medicine doctors
and people who were sort of thinking outside of the box.
Because this is not taught in medical school.
And, you know, ultimately because he had a lot of motivation
and a lot of resourcefulness
and a lot of resources to be able to see
a lot of different doctors, he found some solutions for it.
But it's still very limiting in his life.
And I just wonder about all the people out there
who have not found a solution,
who are just living with brain fog
and with, you know, all of the other crazy stuff
that this does to you every day
and just never figuring it out
and never being able to get any treatment.
My objective, very early on,
I said I wanted to do a mold roundtable.
My objective is that this would be the beginning
of an effort to educate the public,
to educate physicians, to try to figure out
what this agency should be doing,
to try to identify the sources
and then also develop treatments
and prevention strategies so that everybody
who's affected by this disease can get some help.
Too often it's misdiagnosed or undiagnosed
without proper identification.
Patients suffer from severe chronic diseases.
Invasive mold disease can have a 50 to 70% mortality rate.
I'm just reading that.
I didn't even know that.
That's frightening.
On top of that, misdiagnosed patients
often receive antibiotics instead of antifungals.
I know all about that.
They actually need to treat fungal infections.
Misusing antibiotics can contribute to drug resistance.
National surveillance doesn't even exist
for fungal diseases, but analysis,
and maybe that's what we should be doing now at the CDC,
analysis of the limited data we do have
from insurance claims is devastating.
Fungal disease are associated with approximately
7,300 tests, 130,000 hospitalizations,
and 13 million outpatient visits in the U.S. every year.
I think those are probably big underestimates
of the real impact of this.
The total cost associated with fungal disease
is 19 billion annually.
Our hope for today's conversation is that we'll bring
clarity to the gaps in our understanding
of these diseases.
What is the current burden?
What is the role of patients and advocacy groups
in the war on invasive disease?
How can we become better at detecting mold
in our environment?
We have an opportunity to prevent severe illness,
save lives by diagnosing fungal disease,
sooner and treating them smarter.
How we protect patients, workers, and communities,
and how we make America healthy again.
Oh, I'm going to now hand it over to Congressman Fong,
and thank you again for your leadership on this issue.
Well, thank you for your continued leadership,
and thank you for coming out to Bakersfield last month.
It's a community I'm proud to represent,
and it's also where I've seen the issue of fungal disease
through Valley Fever up close.
This is a disease that impacts my friends and neighbors.
It's personal, as you mentioned to me,
the number of, and of course,
he was a former constituent of mine,
and he and I have worked together,
Rob and I, in raising awareness,
but now we're seeing Valley Fever, specifically,
being discovered not just in California,
but across the Western United States,
across the country, broadly.
And so part of the problem is that Valley Fever,
just as your personal experience, is not fully understood,
and it gets misdiagnosed or caught too late
from constituent after constituent,
and I think it's a window into what's happening
with fungal disease more broadly.
This is a critical challenge.
Fungal and mold disease is prevalent well beyond our region,
and it affects communities across the nation,
and our public health response has to reflect that.
We need to incorporate more of the fungal disease,
like Valley Fever, into our broader public health response,
fold it into the infection funding pools
that already exist, instead of being sidelined
as kind of a niche issue.
We need to increase investment in product R&D
so we can better detect, diagnose,
and treat patients with new technologies,
identify early, and then, of course,
when the treatments are available,
provide that treatment immediately.
When there are diagnostic delays,
and Rob will share that, patients feel the consequences,
and those symptoms escalate and it becomes a chronic illness.
Your work to accelerate clinical trials
and spur new cures and treatments,
that's gonna be critical to all of this.
And in the long run, I'd like to see fungal disease
get sustained, dedicated attention.
Mr. Secretary, you've shown that leadership
and what that commitment looks like
with your focus on Lyme disease.
From the tick control pilot program
to the clinician locator partnerships
that you rolled out earlier this year,
we'd like to see that model applied here as well.
Fungal mold disease needs that same level
of sustained investment and attention.
So I just wanna thank you, Secretary Kennedy,
Director Schwartz, Dr. Chow, Dr. Witt.
Thank you for your focus,
your bringing treatment identification,
doctor education, diagnostics, and research development
to bear on this national challenge.
And this is exactly the kind of coordinated effort
our public health system and our community needs.
So I look forward to the continuing partnership
and I thank you so much.
Thank you.
Thank you so much, Representative Fung.
All right, Dr. Schwartz, go ahead.
I know it's so hard to follow these two
august gentlemen here,
but thank you, Secretary Kennedy and Dr. Brenner
and members of Congress for your leadership
in convening this important round table
on invasive mold disease.
This week actually marks 10 years
since the CDC established the Fungal Disease Awareness Week.
This is a decade of working to bring serious mold
and other fungal threats out of the shadows
and into the public health spotlight.
We have made progress, but mold remains a serious
and under-recognized health issue.
From invasive mold disease affecting vulnerable patients
in our healthcare facilities,
to mold in damp or water-damaged homes,
as the Secretary mentioned, and office buildings.
This is not an issue confined to healthcare settings
or major disasters.
It can affect the places where people live,
where they work, where they stay while they're traveling,
and where they receive care.
We know mold exposure can affect health
in a broad range of ways,
but we don't fully understand the extent of its impact.
More research is needed to understand
which conditions may result from mold exposure
and how exposure may worsen existing health conditions.
For people experiencing symptoms,
these unanswered questions underscore the importance
and the urgency of better science, earlier recognition,
and patient-centered care informed
by the best available evidence.
For invasive mold disease,
the challenges in front of us are also clear.
Delays in diagnoses, increasing antifungal resistance,
limited treatment options,
and gaps in surveillance and laboratory testing.
Closing those gaps will require both innovation
and sustained investment.
CDC has long been a public health leader
on mold and other serious fungal diseases,
and we are committed to bringing our experience,
resources, and programs to this broader effort.
That commitment is also part of our shared mission
to make America healthy again.
By identifying health threats earlier,
giving Americans practical information
to protect themselves and their families,
and ensuring patients receive the right care
at the right time.
But addressing these challenges
will take all of us working together across government
and alongside the clinician, patients, researchers,
public health partners,
and industry leaders represented here today.
This year, CDC is taking three important steps
to move from awareness to action.
First, we are improving awareness and education.
CDC is supporting an education campaign
for patients, caregivers, and clinicians,
including more than 1.5 million
in funding to the MyCare Foundation.
Education is one of the fastest
and most cost-effective steps we can take.
Patients and clinicians need to recognize
when invasive mold disease
or another severe fungal infection
may be the reason that someone simply
is not getting better.
And as you mentioned, Secretary,
we don't get this in medical schools.
So this is very important to have this awareness.
Second, we are expanding clinical research capacity
with 2.5 million in funding
to the University of Alabama
Birmingham Mycosis Study Group.
We need better diagnostics, better antifungal treatments,
and stronger clinical trials
so we can diagnose patients sooner,
treat them appropriately,
and reduce avoidable illness, hospitalization, and death.
And third, we are strengthening surveillance
and lab capacity with more than 8.7 million
in funding to 38 states and local health departments.
Improving our nation's public health infrastructure
will give HHS, states, healthcare facilities,
and communities the information they need
to identify threats and act earlier.
None of this work would be possible
without our partners, the support of this administration,
and Congress's commitment to addressing this issue.
Progress depends on earlier diagnosis,
stronger surveillance, prevention and education,
and sustained investment.
We know there are patients living with symptoms
and questions that do not have clear answers.
It is up to us to advocate for them
and make sure their healthcare providers
have the information and the tools they need
to understand the potential health effects of mold
and guide them towards appropriate care.
Patients deserve to be heard.
I'm looking at you, JP, you deserve to be heard.
They deserve a public health and healthcare system
committed to advancing the science
and supporting their care.
CDC is ready to do its part
to build awareness, support healthcare providers,
and partner with patients and communities.
Together, we can protect more Americans,
we can improve our health,
and continue our work to make America healthy again.
Thank you so much.
Thank you.
Very good.
Well, I'm ready to stand up and fist pump.
I mean, we're ready to go here.
Awareness to action and moving health outcomes.
All right, we'll turn to Dr. Chow next.
I have a lot of questions for you,
but we'll keep it concise and let you roll
with a few minutes of what you'd like the group to hear
regarding an overview of fungal disease,
the burden in the US, and emerging health threats.
Go ahead.
Thank you, Dr. Brenner.
Well, let me first begin with what we know
and what we don't know about the burden
of fungal diseases in the US.
And to frame it, there are hundreds of fungal species
that can cause disease in humans.
And some of these are in yeast form,
some of them are in mold form.
And clinically, these diseases,
they present in a variety of ways.
They can be mild, superficial infections like ringworm,
to more severe forms like the fungal pneumonias,
like valley fever,
to, of course, the invasive mold disease.
And you mentioned that statistic
of 50 to 70% mortality rates.
And so there's a variety of diseases.
And we know that the people who are at most risk
for these infections are those that tend to be very sick,
those who are immunosuppressed.
And this is a growing population in the US.
The recent data is showing
that about 7% of adults in the US,
that's one in 15, about 20 million people
are immunosuppressed because of their health condition,
the medications that they're on.
So that's the context.
And for the burden, we don't know the true burden
of fungal diseases in this country.
And Secretary Kennedy, you alluded to this,
those numbers that you mentioned,
over 7,000 deaths per year,
over 130,000 hospitalizations.
When we did those estimates at the CDC,
we see those as likely underestimates
because of what we know for missed infections
and misdiagnoses.
And that's being driven by the gaps in diagnostics
and awareness that we're gonna talk about here today.
And then lastly, I would just say
that for emerging health threats,
we see new fungal species that are emerging.
And sometimes they emerge already resistant
to the few precious drugs that we have already.
And so these gaps of diagnostics
and awareness and surveillance, it's very concerning.
Very good, thank you, Dr. Chow.
Can somebody give us some good news in one of the rounds?
We're gonna identify the issues
we need to solve and address.
All right, we're gonna turn over to Dr. Witt.
I have a few questions for you,
but we'll let you go ahead and get started
on the Georgia Emerging Infections Program,
invasive mold disease surveillance findings
and any gaps that you'd like to highlight.
Yeah, thank you, Dr. Benner.
And thank you all for having me here today.
Just as background,
the Georgia Emerging Infections Program
is a unique and productive collaboration
between the Centers for Disease Control,
Emory University School of Medicine
and the Georgia Department of Public Health.
And at any given time,
we're surveying about 20 diseases across the state of Georgia
including invasive mold disease.
And we're the only program doing that in the country.
And the article that we recently published
with our colleagues at the CDC
described our experience between 2020 and 2024.
And we survey three hospitals in the Atlanta metro area,
a federal facility, a county facility
and a private hospital system.
We found 450 patients with invasive mold disease
in those four years.
And some of the statistics you were quoting,
Secretary Kennedy,
we found those two high rates of mortality,
50% of patients needed mechanical ventilation,
so needed a tube in their lungs to breathe for them.
So highly morbid and mortal condition.
Additionally, we found that
although a lot of patients were immunosuppressed
as Dr. Chow alluded to,
and that means like patients with solid organ transplants,
patients with blood cancers like leukemia and lymphoma,
we did find a rather large number of patients
who didn't have one of those risk factors.
Instead, they maybe had chronic lung disease like COPD,
end stage liver disease,
which in medicine we say cirrhosis, or diabetes.
And even though transplant infectious disease physicians,
infectious disease physicians in general,
like myself and Dr. Pappas,
are aware that those additional diagnoses
may put you at risk for invasive mold disease,
I'm pretty sure that a lot of the primary care physicians
out there taking care of these patients
with chronic lung disease
may not be aware that their patients are at risk.
And so I'm so excited that we're here today
advocating for more information about these diseases,
faster diagnostics, and expanded therapeutics.
I think it's super important for the patients.
I have one question.
400 odd patients that you found in those three facilities,
those were people who were there
because they didn't know they had mold disease
or were they aware of it?
So there's a variety of patients.
They might have come in for,
let's say their bone marrow transplant,
or maybe they came in
because they had a chronic cough or a chronic headache.
So it's really a variety of patients
because we just look at the tests in the lab
and that's how we find the patients.
Did you go and blood test every patient in those hospitals
or how did you discover that they had mold?
So that's a great question.
There's a variety of ways we diagnosed it.
So sometimes it was a blood test.
Sometimes it's tests from the tissue specifically.
So from the lung, from the brain.
And sometimes it's on pathology,
from actual tissue, not even grown in the microbiology lab,
grown, seen by our pathologists.
So it's challenging to diagnose in general.
We can't address what we can't find.
Absolutely.
Could apply to a lot of things.
All right, let's move over to Rob Purdy
on education and patient advocacy.
Go ahead, please.
Yeah, so you wanted some good news?
Let's have it.
Patients have entered the chat and we are not leaving
and we intend to stick around until we get the results
that we need and the answers that we deserve.
So to that effect, you know,
when it comes to research and education,
you know, Mr. Secretary, as you kind of alluded to,
physicians are taught certain things,
but patients, we are experts in and of ourselves.
And we have a lived experience that has a lot of value.
And when we can connect the two things,
we can successfully address an issue.
However, if patients are siloed and not heard,
then things can be missed.
So simple things like when designing a clinical trial,
clinical trials are extremely expensive.
If you look at whether it's approval of a drug
through the FDA or just better therapeutics
and how to better treat a patient,
a poorly designed clinical trial
that doesn't include patient perspective
can lead to a failure to enroll.
Barriers that physicians and scientists haven't considered
may be obvious to patients.
So the way to address the issue is through collaboration,
through folks like Congressman Fong,
through amazing physicians and public health agencies
like we have gathered around this table.
Very good.
Now, patient engagement with FDA,
I'll share that with my colleagues over there.
Have you worked with FDA directly already?
We actually have what they call
external-ed patient-focused drug development meeting
on one of these invasive mold disease scheduled for November
for mucormycosis.
So we have been engaging with the FDA.
Okay, very good.
The lived experience is absolutely critical,
as you point out, and your willingness to share,
we all appreciate.
All right, we will move.
Go ahead, yeah, please.
From the public health perspective from CDC,
it has been so critical to work with patients
like Rob and others
in terms of the health communication campaigns
and how we design them and develop them
so we can get the right message in the right way
to the people who most need to hear it.
I don't want to put Rob on the spot,
but I wonder if you could share his misdiagnosis
and the fact that his illness became worse
until they found out that he did have that.
Yeah, and I would like to add that when I share my story,
it is not indicative of me,
and I'm also gonna be speaking.
I brought two patients and two caregivers with me here
that have personal experience with invasive mold disease,
and I hope they'll allow me to speak for them
a little bit as well.
But imagine waking up with a simple headache
that just doesn't go away and progresses,
and you go to the doctor and they tell you
it's a sinus infection, they give you antibiotics,
and they send you on your way, and it doesn't work.
So fast forward six weeks in the interest of time,
and you're diagnosed with a fungal meningitis.
Six weeks of progression to a fungal meningitis.
I don't know how many of those weeks
I had a fungal meningitis,
but probably at least four of the six.
And I'm considered a success case.
So JP and Jonathan, who I brought here with me,
they also experienced these delays in diagnosis.
And then I was prescribed a treatment,
and this is a drug that you normally take
one or two pills of, and I was taking six a day,
and the goal was I would take six a day
for the rest of my life.
And then I failed that drug,
and then I failed the next drug.
And I don't wanna jump too far ahead,
but I failed the third drug.
And so if you look at this little love tap on my head,
they inserted something called an Amire Reservoir
so they could inject a very toxic old antifungal
directly into my brain.
The good news is it was successful in controlling my disease
but it's not curative.
And the patients that I brought here with me today
also have their own experiences to share
with treatment failure and difficulty with these drugs.
And JP has an amazing story to share about Amphotericin.
So even when you get the diagnosis,
you have to have the treatment,
and the treatments are difficult.
And when you are prescribed a treatment
and it stops or cures a fungal disease,
it doesn't undo the damage done during that time.
And that is why I'm considered a success case.
I didn't have a stroke.
I don't have central nervous system damage,
what they call arachnoiditis.
But I'm never gonna be the same.
My family's never gonna be the same.
I went from being a productive member of society
to being reliant on Medicaid and food stamps.
And thankfully I bounced back, but not everybody does.
And so thank you for taking the time to hear our stories
and to address our issues.
I appreciate it so much.
Incredible and extraordinary diagnostic odyssey
that you went on.
And as Secretary Kennedy shared in his own family,
so many patients are on that very delayed timeline.
And Dr. Schwartz also mentioned this need
for innovation and treatment.
So we're gonna move to those two topics next.
And we're gonna start with diagnostics
and environmental detection.
Dr. Chiller, I'll move to you.
What's the state of fungal diagnostics
and how do we help patients on this diagnostic odyssey?
Go ahead.
Yeah, thanks Dr. Brenner and thanks for having me.
For the last three decades,
I've been focusing on fungal infections.
So it's just a thrill to see this
at being engaged at this level.
Diagnostics are a real challenge in this area.
And we have generally relied on growing the fungus.
And that can take days, weeks, even months.
Sometimes we get a growth of a fungus
after the patient has already passed away.
So we really need to focus on more rapid,
simple diagnostics.
And that's something that I've spent many years doing.
And now I get the ability to do it at a small company
that is focusing specifically on that.
Trying to bring that diagnostic
as close to the patient as possible,
as close to Rob, as close to others as possible
is what we're trying to do.
Make it simple, fast and easy.
And as all of you have said, it's about awareness.
It starts with awareness
because if you don't ask for the test to be done,
it's not gonna be done.
And if you don't do the test,
then you don't identify the pathogen
and you don't know how to manage it,
which people talk about here in a bit.
So I think it's critically important
to put more time and effort into developing diagnostics.
This is a small field, so there's not a lot of incentive.
We need that incentive.
We need to push to do that
so that we can solve these problems.
I think the other real challenge we have,
just to be frank,
is that the cells of fungi
are the most similar to human cells.
And so sometimes detecting them is a challenge
because we're actually cross-reacting
with our own cells in our body.
And fungi are everywhere,
as you talked about in the environment.
And so they can often confuse us if we're looking for them.
Is it a real signal or not a real signal?
These are things that we're constantly struggling with
and trying to work out.
I can't not riff on the topic of diagnostics,
given my history.
So by your estimation,
is it a patient delay to diagnostic testing
that causes much of the delay
of failure to recognize on the clinician's part?
And or are there limitations in the diagnostic technology,
the sensitivity of the assays,
the ability to take them to bedside or to point of need?
How do you think that plays out on that timeline?
Yeah, I mean, I think those are two great points
that are both in play here.
So I think that there are times
where we as physicians do not think fungus.
One of the things we came up with at CDC when I was there
is hashtag think fungus,
because you've got to think about it to order the test.
And so we as physicians often don't think to order them.
So some of these tests are available
and we can order them and we can get them,
but if we're not aware,
and so that's one of the reasons I think
we really want patients to advocate for themselves.
Ask your doctor, hey, do I have a fungal infection?
Like the secretary was saying,
someone comes in, you ask, you ask,
hey, what do I have, can you look for this?
And I think that prompts us as physicians to order tests.
And then on the other side, as I mentioned,
yes, we're struggling in developing what we need.
We need more tests and we need to focus more attention
on developing these tests and we can do it,
but we need more incentive, we need investment,
we need to develop new tests, new rapid tests,
tests that answer the question quickly
and are more specific and sensitive to these diseases.
Okay, I'd like to go more on that,
but we're gonna keep on schedule here.
We'll move over to treatment and Dr. Pappas,
what is the state of antifungal therapeutics
and clinical trials and what is needed
to help intervene earlier and treat earlier
with regards to invasive mold disease
and other severe funguses?
Yeah.
Thank you for the opportunity to be here and discuss this.
By their nature, antifungal trials
with patients with invasive fungal infections are difficult.
They're difficult to enroll.
The patients are common,
but not as common say as a bacterial infection
and so they are a little bit harder to find.
Those patients are difficult to enroll in the trials
because of certain criteria that you have to meet,
not just to have the diagnosis,
but also not be too sick and be sick enough.
And that is the way we have done our studies
with FDA guidance over time.
So that alone is a challenge,
but I think what is really making fungal therapeutics
more difficult nowadays,
and this is somewhat unique to our time
and there are 200 biologics out there.
When we talk about 7% of our adult population
who are immunocompromised,
that's classically immunocompromised.
That doesn't include individuals with diabetes,
for instance.
These are people that are,
many of them are medically compromised.
And so we're challenged with that.
How do you manage the trait of fungal infection
in a person that's also in a biologic?
And so let me provide you two quick examples
of individuals that have the same disease
that are managed completely different.
You know what cryptococcal meningitis is.
Very common in HIV patients,
but we see it in non-HIV patients now more commonly.
Two patients come into my clinic two weeks ago.
One of them is a normal 26-year-old car salesman
with cryptococcal meningitis, improves on therapy,
then six weeks into therapy has what appears
to be a relapse, but it's nothing more
than an inflammatory response to his dying organism.
So here's a fellow with cryptococcal meningitis
we're having to give steroids to,
which is anathema to fungal infection.
You would never think of that,
but that's the correct treatment.
Six months later, he's doing great.
On the other hand, we have an individual
who's a transplant recipient, a heart transplant recipient
with cryptococcal meningitis, can't clear his infection.
He's okay, but we can't clear his infection
because we can't reduce the steroids
and we can't reduce his other immunosuppressants.
So the treatment of fungal infection nowadays
involves not just looking at the antifungals,
of which there are only three classes
and only one of them is orally available,
but also how do you manage the immunosuppressants?
How do you work them into the equation
so that for those who need immunomodulation,
they're available?
And without a good study,
without lots of these types of patients,
it's gonna be very haphazard until then.
For sure.
As a former internist, I can appreciate
the complexity of managing this
on top of other chronic diseases.
Do you feel like ID residents
are getting appropriate training and best practices
for using both diagnostics and appropriate therapeutics?
I mean, I think medical residents
are aware of these more common diseases.
And I think they understand to an extent,
perhaps, the diagnostics.
The diagnostics are what they are.
I mean, they're not perfect,
but they're far better than we had 10 years ago.
Yeah.
Dr. Chiller's gonna fix it.
Yeah, he's gonna fix it.
But as to the issue that Secretary Kennedy
was talking about, which is those individuals
who have mold exposure are sick from it,
everyone is right.
This is not taught.
This is poorly understood.
It's poorly diagnosed,
especially when environmental exposure to mold is universal.
So how one sorts that out
is really sort of a different question
but an important one nonetheless.
Wow, we've identified a lot of gaps.
Did you have a question?
Yeah, I have a question just about diagnostics
and my son's symptoms were things
that I hadn't heard of before.
He felt like he had a bubbling in his brain
and very, very serious brain fog
and then all kinds of other symptoms.
I wonder if there's even a list of sort of symptomologies
so that even AI could then help doctors identify,
are there typical symptoms for it
or is it just all of them?
I mean, I'll start but Pete can add.
Yeah, this is a challenging spectrum of symptoms.
So you can go from indirect exposures
and toxins that are involved in allergic reactions
all the way to these horrible invasive fungi
that are actually in your bloodstream
and causing direct disease.
And so that really gives you an entire spectrum
but I agree that we need to clarify,
classify those patients,
better put that data into large models
and begin to actually develop some using AI
and using other large language models
to begin to understand better symptoms.
I think we understand better those patients
that Pete was describing that are very severe
but patients like your son,
much less, much less understanding as Pete was mentioning
and a wide variety of symptoms.
There isn't one thing we can put our finger on.
I would add to that if I may,
that the commonest disorder
that would kind of fall into this category
is what we would call allergic fungal sinusitis.
And that's never really been studied very well.
These are individuals who feel chronically ill,
they never die of their disease
but they sometimes wish they could
because they feel that way.
And whether we give them any fungals
or whether we give them steroids, it's not clear.
It's not really been studied very well.
They're oftentimes managed by an ENT person
and this is something that is just not really broached
in medical school.
I don't think any of us ever had this.
You learned about crypto and aspergillus
but only in its worst invasive form.
And that's always been kind of the tip of the iceberg.
The other part of this really is submerged
and we don't really understand
what all this mold exposure means.
And moreover, I'm not certain
we have great diagnostics for this.
Is it possible for me to ask
how do you improve continuing education
then if you're learning as you go,
how do you educate doctors who may not be familiar
as they move forward in their career?
You haven't watched Dr. Pappas' videos, his vignettes.
That's how we learn.
Watch some of my videos.
I just wanna take the opportunity to also mention
that infectious disease physicians like Dr. Pappas
and myself who specialize in treating these types
of diseases using the novel diagnostics,
using the novel treatments.
There are not many of us
and actually the number of them are shrinking.
To become an infectious disease physician,
you do residency and then you do
extra training, a fellowship.
And there are multiple fellowships across the country.
Only 50% of those fellowship spots are filled every year.
And many communities, especially rural communities
in the United States do not have
infectious disease physicians serving them.
They may have telehealth infectious diseases
and I'm talking about like the largest hospitals
in pretty large cities like Mobile, Alabama,
not having an infectious disease physician
on site to care for patients.
So I'm so excited we're talking
about diagnostics and therapeutics,
but I think we also need to think about
who's gonna help care for the patients,
who's gonna use these novel technologies.
And we really need to encourage people
to be going into infectious diseases
to help treat these patients.
I'm gonna add regarding how to educate physicians.
It has to be constant and consistent,
but educating physicians isn't enough.
So we know from research done on my disease
that patients who are aware of their,
of the fungal disease has to be tested
and actually reduces the delay in diagnosis.
So you have to educate the population,
you have to educate those at risk
and you have to educate the physicians.
And when you do all of those things,
it can't be in one form.
Dr. Pappas' video is amazing.
He had 40,000 views in six months,
but we live in a country with 350 million people.
It doesn't move the needle.
We need a lot of different tactics
and they have to be sustained.
Fantastic comments today.
And thank you for all sharing your perspectives,
your experience with us.
I couldn't agree more.
There's far more to do, so many gaps,
which we like to call opportunities for improvement.
And with that, I will hand it back over to Mr. Secretary
to close us out with any remarks.
Well, you know, before we close,
maybe we can hear from one of the patients.
If they want to.
I'm Jonathan Ferretti.
I was diagnosed with disseminated scapulariopsis
in July of 2020.
I was diagnosed with amylokemia in September, 2020.
So I was severely immunosuppressed
for a couple of months, several months.
Back in March, 2020,
I was diagnosed with Aspergillus fungus
and got put on some antifungals for that.
And we thought we had cured it.
I ended up going to my stem cell transplant in July
and that's when they found the scapulariopsis.
I turned 18 a couple of days
after they found the scapulariopsis,
which was possibly misdiagnosed back in March as Aspergillus.
Had I not turned 18 right then,
I would not have been able to get on to the trial
that I needed to go on to.
I was treated by Olorefim,
which at the time was a stage two trial drug.
And my doctor said he thinks I had about four days to live
if I did not get on that trial right then.
So yeah, that's my story,
or the very short abbreviated version of my story.
Thank you.
I'll tell you a little bit about my story.
So I was not diagnosed with the sick,
Rob mentioned, it was just a headache
and it wouldn't go away.
That was late 24 until I go to Duke.
And the same neurosurgeons,
or the team that performed brain surgery
on the late sender, Ted Kennedy,
went into my brain
and they are the ones that discovered fungus
taking over my brain.
And soon after that,
my health started declining to where I was paralyzed
and I couldn't talk.
So if it wasn't for my wonderful wife, Jenny,
I wouldn't be here,
but she's been advocating for my disease.
But sometime in December,
of course, I don't remember,
I started inflatericin, B,
and I stayed on that for, gosh, 16 months, I think.
And it was keeping the infection at bay,
but it was also killing me.
My kidneys were failing.
I was getting blood transfusions every other week.
And so then I had the privilege of being invited to NIH.
And under their care,
they pioneered a therapy,
which is why I'm still here.
I'm grateful for the work they do at NIH.
But we started under experimental medication
and that turned a corner for me.
I didn't have to do blood transfusions
and things of that nature.
Was it an antifungal?
It was a novel antifungal.
His company, Eli, has this new antifungal
that's supposed to be replacing inflatericin.
It's been around since the fifties.
I didn't know this,
but there's been no new therapeutic since a long time.
And so the options were limited,
but thankfully the team at NIH
had access to these new therapies
and they made a difference.
You know, I got my life back.
I went back to work.
Yeah, I still have missing parts of my brain,
so I can't remember some things, but it's okay.
And I lost my hearing,
but thankfully the therapy worked
and we're hoping to advance that therapy
and use it on other patients
that have these fungal conditions.
And that brings the importance of there's,
we got to work on new therapies.
We got to work on new outcomes.
Because, you know, even people that are lucky to survive,
I think it's life changing, as Rob mentioned.
Without these little things I have in my ear,
I can't hear.
And, you know, it's hard when you're a family person.
And so I'm grateful for the work that you do.
Thank you very much.
And thank you all.
Thank you to all the panelists for joining us here today.
Thanks for your commitment to solving this problem.
And you helped them in this,
the beginning of a big commitment by my agency
to do more to make sure that people get the right diagnosis,
that there's treatments out there
and that the public and physicians
and providers are informed about how to diagnose it,
how to recognize it.
And for people who come in who are chronically ill,
this is one of the first questions
that should be asked in my view.
Oh, thank you all very much.
And thank you, Congressman Fong.
All right.
Thanks everybody.
Let's give a round of applause to our participants
and our friends, our patrons.
Thank you.
